Table 8. A Summary of Omega-3 Eesential Fatty Acid Studies in Crohn's Disease

Authors	Subjects	Duration	Intervention/Design	Dosage	Outcome
Tsujikawa et al	20 Crohn's Disease patients	1 month	Open trial using diet containing n-3:n-6 ratio of 0.5	Not given	Decreased CRP, improved remission rates
Lorenz et al	39 IBD patients (29 Crohn's Disease patients)	7 months	Double-blind, placebo-controlled crossover of fish oil	1.8 g EPA and 1.3 g DHA daily	Decreased inflammatory mediators TXB2 & LTB4, improved morphology, no change in disease activity
Hillier et al	10 IBD patients	12 weeks	Open label - fish oil versus olive oil	18 g per day, containing 3.2 g EPA, 2.2 g DHA	Decreased inflammatory mediators PGE2, TXB2, & LTB4
Lorenz-Meyer et al	204 Crohn's Disease patients in remission	1 year	Fish oil supplementation compared with placebo or low-carbohydrate diet	6 g daily (containing 3.3 g EPA, 1.8 g DHA)	No Difference in relapse rate in fish oil vs. placebo
Belluzzi et al	78 Crohn's Disease patients in remission	1 year	Double-blind, placebo controlled study of fish oil	4.5 g daily (containing 1.8 g EPA, 0.9 g DHA)	41% fewer relapses in fish oil group; 33% more patients in remission at 1 year
Arslan at al	10 IBD patients (5 Crohn's Disease, 5 Ulcerative Colitis	10 days	Open label pilot study of seal oil	30 mL daily (containing 1.8 g EPA, 2.6 g DHA, 1.0 g DPA)	Decreased disease activity, decreased joint pain

PREVIOUS NEXT